U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. MGH-028AUS 10/814,852 APPLICANT Maurizio Fava et al. FILING DATE GROUP

3626

Page 1 of 1 March 31, 2004 OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

/E.S./		Klein et al.; "Improving Clinical Trials" American Society of Clinical Psychopharmacology Recommendations, Arch Gen Psychiatry/Vol. 59, March 2002, pp. 272-278.
/E.S./		Doody et al.; "Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease", Arch Neurol/Vol. 58, March 2001, pp. 427-433.
/E.S./	*	Grandi; "The Sequential Parallel Comparison Model: A Revolution in the Design of Clinical Trials", Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy, Psychotherapy and Psychosom
/E.S./		Laughren; "The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective", Eur Psychiatry 2001; 16: 418-23.
/E.S./	*	Holbrook et al.; "Innovation and placebos in research: a new design of clinical trial", The Lancet, Vol. 362, December 20/27, 2003, pp. 2036-2037.
/E.S./		Koch et al.; "A Two-Period Crossover Design For The Comparison Of Two Active Treatments And Placebo", Statistics In Medicine, Vol. 8, 487-504 (1989).
/E.S./		Noseworthy et al.; "The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial" American Academy of Neurology, 1994; 44;16-18.
/E.S./		Streiner; "Placebo-controlled trials: when are they needed?" Schizophrenia Research 35 (1999), 201- 210.
/E.S./		Talbot; "The Placebo Prescription", New York Times Magazine, January 9, 2000, 10 pages.
/E.S./		Hrobjartsson et al.; "Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment", Journal of Internal Medicine 2004; 256:91-100.
/E.S./		Hart; "The mysterious placebo effect", Modern Drug Discovery, July/August 1999, 2 (4) 30-40, 7 pages.
/E.S./		Faraone et al., "The Drug-Placebo Response Curve: A New Method for Assessing Drug Effects in Clinical Trials", Journal of Clinical Psychopharmacology: December 2000 – Volume 20 – Issue 6 – pp. 673-679.
/E.S./		Nordenberg; "The Healing Power of Placebos", The Body, FDA Consumer, January/February 2000, 6 pages.
/E.S./		Zelen; "A New Design For Randomized Clinical Trials", The New England Journal of Medicine, Vol. 300, No. 22, May 31, 1979, pp. 1242-1245.
/E.S./		Hrobjartsson et al; "Is the Placebo Powerless? An Analysis of Clinical Trials Comparing Placebo with No Treatment", The New England Journal of Medicine, Vol. 344, No. 21, May 24, 2001, pp. 1594-1603
/E.S./		Ellenberg; "Randomization Designs In Comparative Clinical Trials", The New England Journal of Medicine, Vol. 310, No. 21, May 24, 1984, 1404-1408.
/E.S./		Beller et al.; "Randomisation in clinical trials", MJA, Vol. 177, November 18, 2002, 565-567.
/E.S./		Altman et al.; "Statistics notes How to randomize", BMJ, Volume 319, September 11, 1999, 703-704.
Examiner		/Eliza Squires/ Date Considered: 10/07/2009
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.
(132131-*-)		+ mbig ambigle is not price and There mublished often

^(132131-*-) * This article is not prior art. It was published after the provisional date.